Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
Year: 2021
Type: article
Abstract: Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in overall survival (OS). Superior response rates have been demonstrated with combined PD-1/CTLA-4 blockade, with a significant OS benefit compared with single-agent PD-1 blockade. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers but they have yet to be fully characterized and implemented clinically. Overall, the progress in melanoma therapeutics and translational research will help to optimize treatment regimens to overcome resistance and develop robust biomarkers to guide clinical decision-making. During the Melanoma Bridge meeting (December 3rd-5th, 2020, Italy) we reviewed the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine.
Authors: Paolo A. Ascierto, Christian Blank, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S. Lo, Jason J. Luke, Bart Neyns, Michael A. Postow, Sergio A. Quezada, Michele W. L. Teng, Giorgio Trinchieri, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The Netherlands Cancer Institute, University of Zurich, University Hospital Zurich, National Institutes of Health, National Cancer Institute, Harvard University, Massachusetts General Hospital, Providence Portland Medical Center, University of Chicago, University of Tübingen, Moffitt Cancer Center, Roswell Park Comprehensive Cancer Center, NYU Langone Health, New York University, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Universitair Ziekenhuis Brussel, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, University College London, QIMR Berghofer Medical Research Institute, Center for Cancer Research, European Organisation for Research and Treatment of Cancer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
Funder: Cancer Research UK
Awards: G6229580388, G721865983
OpenAlex ID: W3174692804